vs

Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and Paysign, Inc. (PAYS). Click either name above to swap in a different company.

ADC Therapeutics SA is the larger business by last-quarter revenue ($23.1M vs $22.8M, roughly 1.0× Paysign, Inc.). On growth, Paysign, Inc. posted the faster year-over-year revenue change (45.8% vs 36.4%). Over the past eight quarters, Paysign, Inc.'s revenue compounded faster (31.3% CAGR vs 13.7%).

ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.

Paysign, Inc. is a specialized payment solutions provider that designs and delivers customized prepaid card programs, end-to-end payment processing services, and digital disbursement tools. Its core served segments include healthcare, corporate incentives, and general consumer markets, with primary operations and client bases across North America.

ADCT vs PAYS — Head-to-Head

Bigger by revenue
ADCT
ADCT
1.0× larger
ADCT
$23.1M
$22.8M
PAYS
Growing faster (revenue YoY)
PAYS
PAYS
+9.4% gap
PAYS
45.8%
36.4%
ADCT
Faster 2-yr revenue CAGR
PAYS
PAYS
Annualised
PAYS
31.3%
13.7%
ADCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ADCT
ADCT
PAYS
PAYS
Revenue
$23.1M
$22.8M
Net Profit
$1.4M
Gross Margin
57.7%
Operating Margin
-77.7%
8.1%
Net Margin
6.0%
Revenue YoY
36.4%
45.8%
Net Profit YoY
-0.7%
EPS (diluted)
$0.04
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADCT
ADCT
PAYS
PAYS
Q4 25
$23.1M
$22.8M
Q3 25
$15.8M
$21.6M
Q2 25
$18.1M
$19.1M
Q1 25
$17.4M
$18.6M
Q4 24
$16.9M
$15.6M
Q3 24
$18.0M
$15.3M
Q2 24
$17.0M
$14.3M
Q1 24
$17.8M
$13.2M
Net Profit
ADCT
ADCT
PAYS
PAYS
Q4 25
$1.4M
Q3 25
$-41.0M
$2.2M
Q2 25
$-56.6M
$1.4M
Q1 25
$-38.6M
$2.6M
Q4 24
$1.4M
Q3 24
$-44.0M
$1.4M
Q2 24
$-36.5M
$697.1K
Q1 24
$-46.6M
$309.1K
Gross Margin
ADCT
ADCT
PAYS
PAYS
Q4 25
57.7%
Q3 25
56.3%
Q2 25
61.6%
Q1 25
62.9%
Q4 24
58.9%
Q3 24
55.5%
Q2 24
52.9%
Q1 24
52.6%
Operating Margin
ADCT
ADCT
PAYS
PAYS
Q4 25
-77.7%
8.1%
Q3 25
-196.6%
7.3%
Q2 25
-244.1%
7.5%
Q1 25
-163.5%
13.4%
Q4 24
-191.8%
3.0%
Q3 24
-197.4%
4.5%
Q2 24
-170.5%
0.9%
Q1 24
-188.3%
-2.0%
Net Margin
ADCT
ADCT
PAYS
PAYS
Q4 25
6.0%
Q3 25
-260.1%
10.3%
Q2 25
-313.2%
7.3%
Q1 25
-221.8%
13.9%
Q4 24
8.8%
Q3 24
-244.1%
9.4%
Q2 24
-214.6%
4.9%
Q1 24
-261.1%
2.3%
EPS (diluted)
ADCT
ADCT
PAYS
PAYS
Q4 25
$0.04
$0.02
Q3 25
$-0.30
$0.04
Q2 25
$-0.50
$0.02
Q1 25
$-0.36
$0.05
Q4 24
$-0.26
$0.02
Q3 24
$-0.42
$0.03
Q2 24
$-0.38
$0.01
Q1 24
$-0.56
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADCT
ADCT
PAYS
PAYS
Cash + ST InvestmentsLiquidity on hand
$261.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-185.8M
$48.5M
Total Assets
$323.1M
$276.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADCT
ADCT
PAYS
PAYS
Q4 25
$261.3M
Q3 25
$234.7M
Q2 25
$264.6M
Q1 25
$194.7M
Q4 24
$250.9M
Q3 24
$274.3M
Q2 24
$300.1M
Q1 24
$234.3M
Stockholders' Equity
ADCT
ADCT
PAYS
PAYS
Q4 25
$-185.8M
$48.5M
Q3 25
$-238.2M
$45.8M
Q2 25
$-199.2M
$42.2M
Q1 25
$-238.2M
$39.3M
Q4 24
$-202.6M
$30.4M
Q3 24
$-171.9M
$28.5M
Q2 24
$-131.7M
$26.9M
Q1 24
$-194.4M
$25.5M
Total Assets
ADCT
ADCT
PAYS
PAYS
Q4 25
$323.1M
$276.3M
Q3 25
$289.8M
$209.5M
Q2 25
$321.6M
$193.9M
Q1 25
$272.5M
$205.1M
Q4 24
$322.0M
$179.0M
Q3 24
$349.1M
$167.0M
Q2 24
$371.8M
$182.3M
Q1 24
$308.0M
$173.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADCT
ADCT
PAYS
PAYS
Operating Cash FlowLast quarter
$-31.1M
$48.1M
Free Cash FlowOCF − Capex
$47.5M
FCF MarginFCF / Revenue
208.7%
Capex IntensityCapex / Revenue
0.0%
2.6%
Cash ConversionOCF / Net Profit
35.29×
TTM Free Cash FlowTrailing 4 quarters
$51.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADCT
ADCT
PAYS
PAYS
Q4 25
$-31.1M
$48.1M
Q3 25
$-29.6M
$6.8M
Q2 25
$-24.1M
$3.6M
Q1 25
$-56.3M
$-6.0M
Q4 24
$-21.9M
$14.3M
Q3 24
$-25.0M
$-20.2M
Q2 24
$-32.8M
$20.6M
Q1 24
$-44.1M
$8.2M
Free Cash Flow
ADCT
ADCT
PAYS
PAYS
Q4 25
$47.5M
Q3 25
$6.3M
Q2 25
$3.6M
Q1 25
$-56.6M
$-6.1M
Q4 24
$-21.9M
$14.2M
Q3 24
$-25.3M
$-20.3M
Q2 24
$-32.9M
$20.4M
Q1 24
$-44.6M
$8.2M
FCF Margin
ADCT
ADCT
PAYS
PAYS
Q4 25
208.7%
Q3 25
29.2%
Q2 25
18.6%
Q1 25
-325.2%
-32.9%
Q4 24
-129.8%
91.0%
Q3 24
-140.2%
-133.0%
Q2 24
-193.0%
142.4%
Q1 24
-250.0%
62.1%
Capex Intensity
ADCT
ADCT
PAYS
PAYS
Q4 25
0.0%
2.6%
Q3 25
0.0%
2.1%
Q2 25
0.0%
0.5%
Q1 25
1.5%
0.4%
Q4 24
0.5%
0.7%
Q3 24
1.2%
0.8%
Q2 24
0.2%
1.0%
Q1 24
3.0%
0.4%
Cash Conversion
ADCT
ADCT
PAYS
PAYS
Q4 25
35.29×
Q3 25
3.05×
Q2 25
2.62×
Q1 25
-2.33×
Q4 24
10.43×
Q3 24
-14.03×
Q2 24
29.48×
Q1 24
26.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADCT
ADCT

Segment breakdown not available.

PAYS
PAYS

Plasma Industry$12.6M55%
Pharma Industry$9.6M42%
Other$558.4K2%

Related Comparisons